Snake Farm Feels Bite as Drugmakers Reduce Venom Orders

Tap for Slideshow
Photographer: Balint Porneczi/Bloomberg

Latoxan’s employees extract venom from snakes including deadly black mambas and rattlesnakes by squeezing their jaws with their bare hands, a process they refer to as “milking.”

Close
Photographer: Balint Porneczi/Bloomberg

Latoxan’s employees extract venom from snakes including deadly black mambas and rattlesnakes by squeezing their jaws with their bare hands, a process they refer to as “milking.” Close

Latoxan’s employees extract venom from snakes including deadly black mambas and rattlesnakes by squeezing their jaws... Read More

Photographer: Balint Porneczi/Bloomberg

An employee at the Latoxan SAS laboratory removes a Tropical rattlesnake ahead of extracting the snake's venom at the company's unit in Valence. Close

An employee at the Latoxan SAS laboratory removes a Tropical rattlesnake ahead of extracting the snake's venom at the... Read More

Photographer: Balint Porneczi/Bloomberg

Latoxan CEO Harold de Pomyers said, “Fortunately we only have one accident every 18 months.” Close

Latoxan CEO Harold de Pomyers said, “Fortunately we only have one accident every 18 months.”

Photographer: Balint Porneczi/Bloomberg

One gram of venom can cost as much as 4,000 euros. Close

One gram of venom can cost as much as 4,000 euros.

Photographer: Balint Porneczi/Bloomberg

In the past year, Latoxoan CEO Harold de Pomyers says he has diversified by adding about 3,000 scorpions to the French farm. Close

In the past year, Latoxoan CEO Harold de Pomyers says he has diversified by adding about 3,000 scorpions to the French farm.

Venomous snakes in the French town of Valence are feeling the bite of Europe’s economic crisis.

Latoxan, a company that farms snakes and scorpions to sell their venom to drugmakers including Johnson & Johnson (JNJ), Sanofi (SAN) and Pfizer Inc. (PFE), expects sales to drop 30 percent this year as clients cut back on orders, said Chief Executive Officer Harold de Pomyers.

Pomyers, who with just seven staff took in sales of 1.6 million euros ($2.1 million) in 2011, said he’s reducing his number of snakes to 500 from as many as 800 because of lower demand from Paris-based Sanofi and other drugmakers. Sanofi and Latoxan ended their collaboration this year, a Sanofi spokesman said by e-mail.

“We are currently suffering from the crisis,” Pomyers said in an interview with Bloomberg Television at the company’s headquarters, located in a residential area of Valence, near Lyon. “Sales are falling in European countries such as Italy, Greece or Spain, but also in the United States.”

Latoxan employees extract venom from snakes including deadly black mambas and rattlesnakes by squeezing their jaws with their bare hands, a process they refer to as “milking.” Snakes that are no longer needed will be killed or given away, according to two members of staff who take part in the milking process.

“Fortunately we only have one accident every 18 months,” Pomyers said.

Morphine Alternative

One gram of venom can cost as much as 4,000 euros. The product is used by pharmaceutical companies for research and to manufacture anti-venom, according to Pomyers. Scientists from the Institute of Molecular and Cellular Pharmacology in Sophia Antipolis, France, have isolated two new molecules from black mamba venom and are studying them as a possible alternative to morphine, he said.

About 5 million people worldwide get bitten by snakes each year and an estimated 100,000 die, according to Jean-Philippe Chippaux, a snake expert and director at the Development Research Institute in Cotonou, Benin.

“You need very good venom from good snakes” to make reliable antidotes, says Chippaux. In the past year, Pomyers says he has diversified by adding about 3,000 scorpions to the French farm. Their venom can sell for as much as 35,000 euros a gram.

To contact the reporters on this story: Caroline Connan in Paris at cconnan@bloomberg.net Marthe Fourcade in Paris at mfourcade@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.